? Proteomics (PROT) Shared Resource The UNC Proteomics (PROT) Shared Resource (SR) provides state-of-the-art mass spectrometry-based qualitative and quantitative protein analyses for LCCC members. The PROT SR offers a variety of services to cancer researchers including: guidance in experimental design; protein and peptide identification; relative and absolute protein quantitation; analysis of protein modifications; activity-based proteomics; instrument training; and proteomic informatics. In addition to these basic proteomic services there are four cancer proteomic research themes, each involving active collaborations with LCCC investigators, which have been developed since the last renewal. These themes provide state-of-the art proteomic research technologies to members of the Cancer Center and include: i) chemical proteomics methods to interrogate the dynamic activation state of the cancer kinome; ii) quantifying both the proteome and phosphoproteome of patient tumors as part of the NCI CPTAC initiative; iii) mass spectrometry and computational methods for defining protein-protein interaction networks in cancer, including quantitative measurement of network dynamics; and iv) absolute quantification of proteins in complex protein mixtures by selective reaction monitoring (SRMs). The PROT SR is led by Lee Graves (MT), Professor of Pharmacology and director, and David Smalley, Facility Director. Three additional faculty are directly involved with the efforts of the PROT SR: Gary Johnson (MT), Kenan Distinguished Professor and Chair of the Department of Pharmacology and co-director of the Molecular Therapeutics Program, Ben Major (CCB), Associate Professor of Cell Biology & Physiology, and Xian Chen (IM), Professor of Biochemistry & Biophysics and technology director of the PROT SR. Together they provide strong synergistic leadership in mass spectrometry based proteomics with a proven record of productive collaboration with investigators in the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-44
Application #
9834850
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications